TG Therapeutics (NASDAQ:TGTX) Announces Earnings Results

TG Therapeutics (NASDAQ:TGTX - Get Free Report) issued its quarterly earnings data on Monday. The biopharmaceutical company reported $0.15 EPS for the quarter, topping analysts' consensus estimates of $0.09 by $0.06, Zacks reports. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%.

TG Therapeutics Price Performance

Shares of TG Therapeutics stock traded up $4.33 during mid-day trading on Monday, reaching $34.42. 13,494,362 shares of the stock traded hands, compared to its average volume of 2,441,278. The stock has a market capitalization of $5.36 billion, a PE ratio of -344.17 and a beta of 2.26. The business has a 50-day moving average of $30.79 and a 200 day moving average of $28.24. TG Therapeutics has a fifty-two week low of $12.93 and a fifty-two week high of $36.84. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27.

Insider Transactions at TG Therapeutics

In other news, CFO Sean A. Power sold 10,021 shares of the firm's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $28.53, for a total value of $285,899.13. Following the transaction, the chief financial officer now directly owns 660,611 shares of the company's stock, valued at approximately $18,847,231.83. This trade represents a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 10.50% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on TGTX. StockNews.com lowered shares of TG Therapeutics from a "hold" rating to a "sell" rating in a research report on Friday, January 31st. JPMorgan Chase & Co. lifted their price target on TG Therapeutics from $30.00 to $43.00 and gave the company an "overweight" rating in a research note on Monday, November 25th. HC Wainwright reissued a "buy" rating and issued a $55.00 price objective on shares of TG Therapeutics in a report on Wednesday, January 15th. Finally, The Goldman Sachs Group boosted their price objective on TG Therapeutics from $20.00 to $22.00 and gave the company a "neutral" rating in a research report on Tuesday, November 5th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $40.67.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.